Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board, the company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis. Patients currently enrolled in BEACON-IPF will remain in the trial. Enrollment and dosing have been paused while data is reviewed to understand the DSMB’s rationale for their recommendation. Blinding of the study will be maintained to preserve trial integrity. The company has informed BEACON-IPF clinical trial investigators and is in the process of informing global regulatory authorities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
Questions or Comments about the article? Write to editor@tipranks.com